A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2015

At a glance

  • Drugs Vadimezan (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTRACT-1
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 29 Jun 2012 Companies added in the association field as reported by EudraCT.
    • 03 May 2012 Additional trial locations added as reported by ClinicalTrials.gov.
    • 24 Mar 2012 This trial has been completed in Belgium, Hungary, Poland, Greece and discontinued in Czech Republic, Germany, Italy, Netherlands, Sweden.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top